Replies to post #117359 on Biotech Values

[masterlongevity]

They are not going to get too many patients' PET scans for only $700K. the radioligand is very expensive and so are the PET scnas. My estimate is that they can get only about 60 scans for this amount. That would be 30 baseline and 30 at 1 yr. very small sample

[mcbio]

Pran getting another $700,000 from ADDF and announces plans for small phase II trial to get lots of PET scan pictures of brains and amyloid neroimaging on drug and not on drug, they want pictures of "target engagement" and want to see metals move around and cognitive improvements. I don't think they care at all about plaque reduction.

How likely is it they land a partner from this data if it's positive? They seem to be guiding that this data, due in early 2013, could lead to a partnership but I know they've been guiding for a partnership for a long time.

Also looks like they plan to start a Phase 2 in Huntington's disease later this year for PBT2 as well that is also supposed to read out in 2013. So, 2013 is going to be a year of important newsflow for PRAN. Just hard to gauge if any of this data would lead to a nice partnership for them.